Data Presented At The American Society of Hematology 49th Meeting Demonstrate That Incyte Corporation’s Novel JAK Inhibitor, INCB18424, Provides Rapid and Profound Clinical Benefits in Myelofibrosis Patients

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today the presentation of interim Phase I/II results of INCB18424, its orally available janus-associated kinase (JAK) inhibitor in patients with myelofibrosis (MF). MF is a serious neoplastic condition with a survival rate of 3 to 7 years that is characterized by varying degrees of bone marrow failure, life-threatening splenic enlargement, and marked constitutional symptoms, resulting in a significant loss in quality of life.